ClinicalTrials.gg
Not yet recruitingNCT07216963CROSSROADSUpdated Oct 14, 2026

The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study

An interventional study of Community Paramedic Standard of Care (CP SOC) and CROSSROADS in Opioid Use Disorder, Overdose, Drug and Overdose, sponsored by Duke University. Not yet recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Duke University · Not applicable, Interventional, and Health services research

How we know

Updated Oct 14, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Planned enrollment
116th of 1,098
400 · median 56
Started
2027
with 17 others
No phase
571 of 1,223
133 open now
Primary completion
2029-09
later than 292 of 315 live
Registered
1,151st of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 116th largest by planned enrollment of the 1,098 interventional ones that give a count, is one of 18 that started in 2027, is one of 571 with no phase, reaches primary completion later than 292 of the 315 other live ones, and was the 1,151st registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to develop and test the CROSSROADS intervention. CROSSROADS is designed for people who have recently survived an opioid and/or stimulant-related non-fatal overdose and had contact with staff from a Community Paramedic (CP) program.

Participants will be randomly placed into one of two groups:

1) Standard of care from the CP program, or 2) CROSSROADS, which includes CP care plus a Medical-Legal Partnership (MLP). The MLP helps people with legal problems that can affect their health-- like issues with housing or public benefits.

Researchers will test if the CROSSROADS intervention reduces drug use and involvement with the criminal legal system.

People in the study will be followed for one year and asked to complete surveys at the beginning, and again at 1 month, 6 months, and 12 months.

Read the detailed description

CROSSROADS is a Hybrid Type I Implementation Effectiveness Trial. The primary objective of the study is to examine how the CROSSROADS intervention, which incorporates a Medical-Legal Partnership (MLP) into community paramedic (CP) standard of care, addresses health-harming legal needs (HHLN) influencing adverse substance use outcomes and risk of CLS (Criminal Legal System) engagement.

The key component of the CROSSROADS intervention is that it directly identifies and addresses HHLN. The MLP utilized in this study is Docs for Health (D4H), a technology-supported mobile application MLP that utilizes a 'screen and intervene' approach.

The primary aim is to compare the CROSSROADS intervention versus standard of care (SOC) CP programs across four sites (Durham, NC; Miami, FL; Pittsburgh, PA; Portland, ME) on 1) frequency of opioid and stimulant use, and 2) CLS (police, incarceration, and probation/parole) involvement. Researchers will randomly assign 400 adults to the SOC CP program (n=200) or CROSSROADS (n=200). Follow-up will occur at 1, 6, and 12 months.

The focus of the study is to examine how Community paramedic programs addressing socio-structural-legal factors influence adverse substance use outcomes and risk of criminal legal engagement. The long-term goal is to assess how innovative non-carceral interventions can be best implemented to address adverse substance use outcomes and prevent CLS exposure.

03

Conditions studied

  • Opioid Use Disorder
  • Overdose, Drug
  • Overdose
  • Substance Use (Drugs, Alcohol)

Keywords

  • Overdose
  • Community Paramedic
  • Medical-Legal Services
  • Criminal Legal System
  • Consolidated Framework for Implementation Research
  • Paramedical Personnel
  • Human Centered Design
  • Criminal Legal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or older;
  • Has interacted with a CP team (and, thus, experienced a non-fatal opioid and/or stimulant overdose) in the last 30 days;
  • Has independent legal agency
  • Able to independently provide ; and
  • Able to speak and understand English.

Exclusion criteria

Exclusion Criteria:

- Active, severe, and untreated mental illness that would make providing consent impossible

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Community Paramedic Standard of Care (CP SOC)

    The community paramedic (CP) standard of care (SOC) has three basic components across all study sites. The core components of the CP SOC are that CPs: 1) are deployed via 911 as an opioid and/or stimulant overdose response; 2) provide Medications for Opioid Use Disorder (MOUD), harm reduction service referrals, and link patients to health and social programs as needed; and 3) provide long-term follow-up care in the field after initial contact.

    Behavioral: Community Paramedic Standard of Care (CP SOC)

  • Experimental
    CROSSROADS

    The community paramedic (CP) standard of care (SOC) has three basic components across the sites. The core components of the CP SOC are that CPs: 1) are deployed via 911 as an opioid and/or stimulant overdose response; 2) provide Medications for Opioid Use Disorder (MOUD), harm reduction service referrals, and link patients to health and social programs as needed; and 3) provide long-term follow-up care in the field after initial contact. The CROSSROADS intervention will utilize these SOC aspects and build in technology-supported medical-legal partnerships (MLP) via Docs for Health (D4H) that identifies and addresses health-harming legal needs (HHLN). While CP SOC may refer to services that address some HHLN, the key component of the CROSSROADS intervention is the direct identification and addressing of HHLN via D4H.

    Behavioral: CROSSROADS

Interventions

  • BehavioralCommunity Paramedic Standard of Care (CP SOC)

    Participants randomized to CP SOC will receive 1) community paramedic standard of care after initial response to overdose; 2) Medications for Opioid Use Disorder (MOUD), harm reduction referrals, and linkages to health and social programs as needed; 3) long-term follow-up care with community paramedics in the field after initial contact.

  • BehavioralCROSSROADS

    The community paramedic (CP)standard of care (SOC) has three basic components across the sites. The core components of the CP SOC are that CPs: 1) are deployed via 911 as an opioid and/or stimulant overdose response; 2) provide Medications for Opioid Use Disorder (MOUD), harm reduction service referrals, and link patients to health and social programs as needed; and 3) provide long-term follow-up care in the field after initial contact. The CROSSROADS intervention will utilize these SOC aspects and build in technology-supported medical-legal partnerships (MLP) via Docs for Health (D4H) that identifies and addresses health-harming legal needs (HHLN). While CP SOC may refer to services that address some HHLN, the key component of the CROSSROADS intervention is the direct identification and addressing of HHLN via D4H.

06

What researchers measure

Primary outcomes

  1. Frequency of opioid and/or stimulant use

    As measured by the number of days of use per month per participant.

    Time frame: 12 months

  2. Number of participants with opioid and/or stimulant use

    As measured by Urine Drug Screen (UDS).

    Time frame: 12 months

  3. Number of participants with Criminal Legal System Involvement

    Measured by the number of participants with criminal legal system involvement. Criminal legal system involvement includes all intercepts of the Sequential Intercept Model: police/arrest, jail, court, prison, and community supervision.

    Time frame: 12 months

Secondary outcomes

  1. Presence of Health Harming Legal Needs (HHLN)

    Measured by the National Center for MLP HHLN Scale, which measures HHLN including income, education \& employment, legal status, and personal stability. The scale "score" is the number of positive responses, indicating the number of identified legal needs a patient has on the screening tool.

    Time frame: 12 months

  2. Number of participants with risky substance use behaviors

    Measured by the HIV Risk-taking Behavior Scale (HRBS). The HRBS provides three scores: a total score indicating level of HIV risk-taking behavior; a Drug Use Sub-total indicating level of risk due to drug taking practices; and a Sexual Behavior Sub-total indicating level of risk associated with unsafe sex. The higher the total score, the greater the risk the subject has of contracting and passing on HIV.

    Time frame: 12 months

  3. Risk of overdose as measured by the Opioid Overdose Risk Behavior Scale, version 2 (ORBS-2)

    The total score on the ORBS-2 indicates the level of risk, with a higher score signifying a greater risk of overdose.

    Time frame: 12 months

  4. Number of participants who experienced a non-fatal overdose as measured by health record

    Non-fatal overdoses measured by administrative/health records.

    Time frame: 12 months

  5. Number of participants who experienced a fatal overdose

    Fatal overdoses are measured by administrative/health records.

    Time frame: 12 months

  6. Treatment utilization

    Number of participants who utilized treatment services

    Time frame: 12 months

  7. Prevention service utilization

    Number of participants who utilized overdose prevention services

    Time frame: 12 months

  8. HHLN Service Utilization

    Number of participants who utilized HHLN (Health Harming Legal Needs) ameliorative services

    Time frame: 12 months

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Sep 2029, 31 months later.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 31 months is close to that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Feb 2027, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2025
First posted
Oct 15, 2025
StartEst.
Feb 1, 2027was Sep 2026
Primary completionEst.
Sep 1, 2029
CompletionEst.
Aug 1, 2030
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Feb 1, 2027
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Start date Sep 1, 2026→Feb 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07216963
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Oct 15, 2025
Start date
Feb 1, 2027 (estimated)
Primary completion
Sep 1, 2029 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Oct 14, 2026

Study contacts

Margaret Roach, MPH
Contact
margaret.roach@duke.edu
919-660-3008
Lauren Brinkley-Rubinstein, PhD
principal investigator · Duke Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion